High-Purity (R)-3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE (CAS 137036-55-6): A Key Pharmaceutical Intermediate Supplier

Discover the critical role of (R)-3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE (CAS 137036-55-6) in advancing pharmaceutical research and development. As a leading manufacturer and supplier in China, we provide high-quality intermediates essential for creating novel therapeutics targeting neurological and psychiatric disorders. Explore our reliable sourcing options and competitive pricing for this vital compound.

Get a Quote & Sample

Why Choose Our Pharmaceutical Intermediates

Uncompromised Quality and Purity

Our (R)-3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE (CAS 137036-55-6) is manufactured to the highest standards, ensuring the purity required for demanding pharmaceutical applications and successful drug development.

Expertise in Pharmaceutical Intermediates

Leverage our deep understanding of pharmaceutical intermediates, including compounds like C10H12N2O, to accelerate your research and production timelines. We support your journey from discovery to market.

Global Supply Chain Reliability

As a trusted manufacturer and supplier in China, we offer a stable and efficient supply chain for (R)-3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE, ensuring timely delivery for your critical projects.

Key Applications in Pharmaceutical R&D

Neurological Disorder Therapeutics

Investigate and develop novel treatments for neurological conditions by utilizing (R)-3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE as a core intermediate.

Psychiatric Disorder Research

Advance your research into psychiatric disorders with a reliable source of high-quality intermediates like C10H12N2O.

Advanced Drug Design

Our (R)-3-AMINO-2,3,4,5-TETRAHYDRO-1H-1-BENZAZEPIN-2-ONE serves as an excellent starting point for drug design and optimization, leading to improved therapeutic profiles.

Synthesis of Active Pharmaceutical Ingredients (APIs)

Essential for the precise synthesis of APIs, ensuring the efficacy and safety of the final pharmaceutical products.